Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
BriaCell Therapeutics ( (TSE:BCT) ) has issued an announcement.
BriaCell Therapeutics has received a positive recommendation from the Data Safety Monitoring Board to continue its pivotal Phase 3 study of Bria-IMT plus an immune checkpoint inhibitor for metastatic breast cancer, with no safety concerns identified. This development underlines the potential of BriaCell’s novel immunotherapy to significantly impact cancer treatment, particularly in improving survival and quality of life for patients with metastatic breast cancer.
More about BriaCell Therapeutics
BriaCell Therapeutics Corp. is a clinical-stage biotechnology company focused on developing novel immunotherapies to transform cancer care. The company is involved in creating innovative treatments aimed at addressing urgent medical needs in the oncology sector.
YTD Price Performance: -49.47%
Average Trading Volume: 11,565
Technical Sentiment Consensus Rating: Buy
Current Market Cap: C$20.59M
For detailed information about BCT stock, go to TipRanks’ Stock Analysis page.